source
- Agios pays $25 million for global rights to Oscotec’s SYK inhibitor cevidoplenibAgios Therapeutics announced it has secured an exclusive worldwide license for Oscotec’s experimental SYK inhibitor, cevidoplenib. Under the agreement, Agios will pay $25 million up front to Oscot…
- Avenzo Therapeutics to go public via reverse merger with Rallybio after Candid partnership endsOn June 1, 2026, Avenzo Therapeutics announced that it will become a publicly traded company through a reverse merger with Rallybio, securing a Nasdaq listing after its previous partner, Candid, en…